ESR1 and breast cancer: In conclusion, we report the results of a second prospective-retrospective validation study demonstrating the clinical validity of MetaSite Score in patients with ER+/HER2- breast cancer and show for the first time that it provides complementary prognostic information to Recurrence Score, specifically for early recurrence within 5 years of diagnosis.